[PDF][PDF] Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia
W Blum, RB Klisovic, B Hackanson, Z Liu… - Journal of Clinical …, 2007 - researchgate.net
Journal of Clinical Oncology, 2007•researchgate.net
Phase I Study of Decitabine Alone or in Combination With Valproic Acid in Acute Myeloid
Leukemia Page 1 Phase I Study of Decitabine Alone or in Combination With Valproic Acid in
Acute Myeloid Leukemia William Blum, Rebecca B. Klisovic, Bjoern Hackanson, Zhongfa Liu,
Shujun Liu, Hollie Devine, Tamara Vukosavljevic, Lenguyen Huynh, Gerard Lozanski, Cheryl
Kefauver, Christoph Plass, Steven M. Devine, Nyla A. Heerema, Anthony Murgo, Kenneth K.
Chan, Michael R. Grever, John C. Byrd, and Guido Marcucci A B S T R A C T Purpose To …
Leukemia Page 1 Phase I Study of Decitabine Alone or in Combination With Valproic Acid in
Acute Myeloid Leukemia William Blum, Rebecca B. Klisovic, Bjoern Hackanson, Zhongfa Liu,
Shujun Liu, Hollie Devine, Tamara Vukosavljevic, Lenguyen Huynh, Gerard Lozanski, Cheryl
Kefauver, Christoph Plass, Steven M. Devine, Nyla A. Heerema, Anthony Murgo, Kenneth K.
Chan, Michael R. Grever, John C. Byrd, and Guido Marcucci A B S T R A C T Purpose To …
Purpose
To determine an optimal biologic dose (OBD) of decitabine as a single agent and then the maximum-tolerated dose (MTD) of valproic acid (VA) combined with decitabine in acute myeloid leukemia (AML).
researchgate.net